Published in J Virol on April 01, 1995
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest (1996) 4.10
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol (1996) 2.47
Cytotoxic T cells and viral hepatitis. J Clin Invest (1997) 2.46
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol (1999) 1.93
Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol (2002) 1.81
Retracted Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.51
Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest (1997) 1.50
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol (2005) 1.48
Hepatitis C virus core protein enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor ligand and tumor necrosis factor alpha. J Virol (1999) 1.45
Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol (1997) 1.42
Progress on new vaccine strategies against chronic viral infections. J Clin Invest (2004) 1.38
Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV. J Virol (2001) 1.34
Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med (1999) 1.28
Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut (1999) 1.26
Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot" J Transl Med (2005) 1.13
Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res (2010) 1.10
Patr-A and B, the orthologues of HLA-A and B, present hepatitis C virus epitopes to CD8+ cytotoxic T cells from two chronically infected chimpanzees. J Exp Med (1996) 1.08
Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest (1998) 1.06
Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. J Virol (2004) 1.06
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol (2007) 0.99
Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol (2004) 0.99
Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol (1996) 0.97
Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies. J Virol (2002) 0.92
Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin Vaccine Immunol (2010) 0.89
Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol (2002) 0.89
Phenotyping of intrahepatic and peripheral blood lymphocytes in patients with chronic hepatitis C. Dig Dis Sci (1997) 0.86
Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes. World J Gastroenterol (2001) 0.84
Cross-linking of Fc(gamma)-receptor on monocytes inhibits hepatitis C virus-specific cytotoxic T-lymphocyte induction in vitro. Immunology (1998) 0.84
Hepatitis C virus: molecular biology and genetic variability. Dig Dis Sci (1996) 0.81
CD28-negative CD8-positive cytotoxic T lymphocytes mediate hepatocellular damage in hepatitis C virus infection. J Clin Immunol (2003) 0.80
Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier. World J Gastroenterol (2006) 0.80
Serum levels of IgG to the peptide of HCV1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients. Med Microbiol Immunol (2007) 0.79
Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine. Immunogenetics (2007) 0.79
Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development. Hum Vaccin Immunother (2014) 0.77
Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro. J Clin Immunol (1997) 0.76
Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist (2015) 0.75
Isolation of a monoclonal antibody from a phage display library binding the rhesus macaque MHC class I allomorph Mamu-A1*001. PLoS One (2017) 0.75
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A (1991) 14.05
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (1993) 9.81
Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol (1989) 8.84
Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 8.47
Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol (1991) 8.33
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol (1993) 8.07
Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A (1990) 6.96
Cytotoxic T-cell memory without antigen. Nature (1994) 6.55
Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science (1992) 5.99
Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (1990) 5.41
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology (1992) 5.16
T-cell antigenic sites tend to be amphipathic structures. Proc Natl Acad Sci U S A (1985) 5.05
Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J Gen Virol (1991) 5.03
Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J Immunol (1987) 4.95
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol (1993) 4.35
Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol (1994) 4.34
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J Virol (1994) 3.61
Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology (1986) 3.59
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med (1989) 3.45
The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell (1993) 3.44
Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci U S A (1991) 3.34
Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology (1992) 3.22
Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol (1992) 3.13
Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol (1981) 3.01
The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA. Virology (1992) 2.88
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol (1993) 2.57
Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J Clin Invest (1994) 2.57
Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals. Virus Res (1992) 2.56
T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology (1993) 2.39
Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet (1993) 2.23
Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J Exp Med (1992) 2.22
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet (1994) 2.01
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med (1993) 1.90
Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol (1994) 1.80
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 1.79
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994) 1.68
Effector T-cell induction and T-cell memory versus peripheral deletion of T cells. Immunol Rev (1993) 1.61
Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol (1993) 1.57
Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A (1994) 1.56
Structure of peptides associated with MHC class I molecules. Curr Opin Immunol (1994) 1.53
Molecular cloning and heterogeneity of the human hepatitis C virus (HCV) genome. J Hepatol (1993) 1.50
HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology (1993) 1.36
Molecular structure of the Japanese hepatitis C viral genome. FEBS Lett (1991) 1.34
Activation of naive, memory and effector T cells. Curr Opin Immunol (1994) 1.34
Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. Eur J Immunol (1992) 1.30
Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology (1992) 1.26
Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol (1994) 1.20
Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J Virol (1992) 1.14
Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology (1993) 1.14
The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses. Curr Top Microbiol Immunol (1994) 1.04
Analysis of mutant HLA-A2 molecules. Differential effects on peptide binding and CTL recognition. J Immunol (1994) 0.96
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
Flavivirus genome organization, expression, and replication. Annu Rev Microbiol (1990) 14.20
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science (1985) 8.54
Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 8.47
Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 7.53
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
Complete nucleotide sequence of the genomic RNA of Sindbis virus. Virology (1984) 6.60
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med (1991) 6.09
Nucleotide sequence of the 26S mRNA of Sindbis virus and deduced sequence of the encoded virus structural proteins. Proc Natl Acad Sci U S A (1981) 6.08
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med (1995) 5.98
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol (2000) 5.26
Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol (2000) 5.17
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science (1989) 4.84
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. J Virol (1996) 4.59
Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol (1989) 4.46
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A (1993) 4.30
Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol (1994) 4.21
Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol (1993) 4.19
trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J Virol (1997) 4.17
Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci U S A (1990) 4.12
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell (1996) 4.12
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J Virol (1994) 3.61
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Sindbis virus proteins nsP1 and nsP2 contain homology to nonstructural proteins from several RNA plant viruses. J Virol (1985) 3.51
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol (1991) 3.41
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol (1993) 3.37
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences. J Mol Biol (1987) 3.30
The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology (2001) 3.25
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Polypeptide requirements for assembly of functional Sindbis virus replication complexes: a model for the temporal regulation of minus- and plus-strand RNA synthesis. EMBO J (1994) 3.00
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med (1990) 2.99
An SNP map of human chromosome 22. Nature (2000) 2.99
Association of sindbis virion glycoproteins and their precursors. J Mol Biol (1982) 2.95
Mapping of RNA- temperature-sensitive mutants of Sindbis virus: complementation group F mutants have lesions in nsP4. J Virol (1989) 2.94
Sequence coding for the alphavirus nonstructural proteins is interrupted by an opal termination codon. Proc Natl Acad Sci U S A (1983) 2.94
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol (2000) 2.89
Yellow fever virus proteins NS2A, NS2B, and NS4B: identification and partial N-terminal amino acid sequence analysis. Virology (1989) 2.87
Formation of native hepatitis C virus glycoprotein complexes. J Virol (1997) 2.87
Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc Natl Acad Sci U S A (1992) 2.86
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Sequence studies of several alphavirus genomic RNAs in the region containing the start of the subgenomic RNA. Proc Natl Acad Sci U S A (1982) 2.77
HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest (1995) 2.66
Association of the Sindbis virus RNA methyltransferase activity with the nonstructural protein nsP1. Virology (1989) 2.64
Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. J Virol (1994) 2.64
Endoscopic lithotomy of common bile duct stones with sublingual nitroglycerin and guidewire. Am J Gastroenterol (1997) 2.62
Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med (1995) 2.61
Mutagenesis of the in-frame opal termination codon preceding nsP4 of Sindbis virus: studies of translational readthrough and its effect on virus replication. J Virol (1989) 2.59
Immunological self, nonself discrimination. Science (1987) 2.59
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site. J Virol (1993) 2.56
Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. J Virol (1996) 2.53
Production of yellow fever virus proteins in infected cells: identification of discrete polyprotein species and analysis of cleavage kinetics using region-specific polyclonal antisera. Virology (1990) 2.50
Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells. J Virol (1999) 2.49
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol (1996) 2.47
Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2001) 2.45
Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J Virol (1999) 2.44
Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc Natl Acad Sci U S A (1998) 2.44
Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. J Virol (1997) 2.39
Ross River virus 26 s RNA: complete nucleotide sequence and deduced sequence of the encoded structural proteins. Virology (1983) 2.38
Synthesis, cleavage and sequence analysis of DNA complementary to the 26 S messenger RNA of Sindbis virus. J Mol Biol (1981) 2.38
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Spontaneous bacterial peritonitis caused by infection with Listeria monocytogenes: a case report and review of the literature. Am J Gastroenterol (1998) 2.35
Genotypic analysis of hepatitis C virus in American patients. Hepatology (1994) 2.33
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
Secondary structure determination of the conserved 98-base sequence at the 3' terminus of hepatitis C virus genome RNA. J Virol (1997) 2.30
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29